Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Market Closed - Nasdaq Other stock markets 01:30:00 08/05/2024 am IST			5-day change	1st Jan Change
5.68 ^USD	+0.35%		+9.02%	-43.93%

01/05	Editas Medicine, Bristol-Myers Squibb Extend Alpha-Beta T Cell Collaboration	MT
01/05	Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events	02/05	GL
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration	01/05	GL
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting	23/04	GL
Editas Medicine : April 2024 Corporate Presentation	12/04	PU
Editas Medicine : Corporate Effectiveness Report April 2024	12/04	PU
Editas: Q4 Earnings Snapshot	28/02	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates	28/02	AQ
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02	GL
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events	21/02	AQ
Editas Medicine to Participate in Upcoming Investor Conferences	31/01	GL
Editas Medicine to Participate in Upcoming Investor Conferences	31/01	AQ
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01	GL
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference	08/01	AQ
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference	03/01	GL
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12	GL
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9	13/12	AQ
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar	11/12	GL
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar	11/12	AQ
Retinitis Pigmentosa Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated)	13/11	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Editas Medicine, Inc.

Equities

EDIT

US28106W1036

Press Releases

Filters